303 related articles for article (PubMed ID: 10192785)
1. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI
Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785
[TBL] [Abstract][Full Text] [Related]
2. Immunochemical analysis of dopamine transporter protein in Parkinson's disease.
Miller GW; Staley JK; Heilman CJ; Perez JT; Mash DC; Rye DB; Levey AI
Ann Neurol; 1997 Apr; 41(4):530-9. PubMed ID: 9124811
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
[TBL] [Abstract][Full Text] [Related]
4. Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum.
Caudle WM; Richardson JR; Wang M; Miller GW
Neurotoxicology; 2005 Aug; 26(4):721-728. PubMed ID: 16112329
[TBL] [Abstract][Full Text] [Related]
5. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
6. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure.
Harvey DC; Laćan G; Melegan WP
Exp Brain Res; 2000 Aug; 133(3):349-58. PubMed ID: 10958525
[TBL] [Abstract][Full Text] [Related]
7. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
[TBL] [Abstract][Full Text] [Related]
8. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
[TBL] [Abstract][Full Text] [Related]
9. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
10. Imaging the vesicular monoamine transporter.
Frey KA; Koeppe RA; Kilbourn MR
Adv Neurol; 2001; 86():237-47. PubMed ID: 11553983
[TBL] [Abstract][Full Text] [Related]
11. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
12. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
13. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
Meyer P; Bohnen NI; Minoshima S; Koeppe RA; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
Neurology; 1999 Jul; 53(2):371-4. PubMed ID: 10430428
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporters and neuronal injury.
Miller GW; Gainetdinov RR; Levey AI; Caron MG
Trends Pharmacol Sci; 1999 Oct; 20(10):424-9. PubMed ID: 10498956
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.
Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC
Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752
[TBL] [Abstract][Full Text] [Related]
16. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
17. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
19. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
[TBL] [Abstract][Full Text] [Related]
20. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.
Tian L; Karimi M; Loftin SK; Brown CA; Xia H; Xu J; Mach RH; Perlmutter JS
PLoS One; 2012; 7(2):e31439. PubMed ID: 22359591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
